Anixa Biosciences, Inc.ANIXNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank46
3Y CAGR-47.7%
5Y CAGR+51.4%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
-47.7%/yr
vs +54.8%/yr prior
5Y CAGR
+51.4%/yr
Recent deceleration
Acceleration
-102.5pp
Decelerating
Percentile
P46
Within normal range
vs 5Y Ago
7.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q1 2026 | 5.39% |
| Q4 2025 | -17.41% |
| Q3 2025 | 19.75% |
| Q2 2025 | 12.44% |
| Q1 2025 | -132.97% |
| Q4 2024 | 400.00% |
| Q3 2024 | -1.63% |
| Q2 2024 | 1.60% |
| Q1 2024 | -15.61% |
| Q4 2023 | -6.66% |
| Q3 2023 | -23.25% |
| Q2 2023 | 4.08% |
| Q1 2023 | 37.64% |
| Q4 2022 | -24.01% |
| Q3 2022 | 26.08% |
| Q2 2022 | 7.69% |
| Q1 2022 | 0.00% |
| Q4 2021 | 7.14% |
| Q3 2021 | -67.26% |
| Q2 2021 | 4.67% |
| Q1 2021 | 0.68% |
| Q4 2020 | 19.64% |
| Q3 2020 | 8.33% |
| Q2 2020 | 7.69% |
| Q1 2020 | -30.00% |
| Q4 2019 | 9.09% |
| Q3 2019 | 15.38% |
| Q2 2019 | 48.00% |
| Q1 2019 | 10.71% |
| Q4 2018 | 6.67% |
| Q3 2018 | -263.64% |
| Q2 2018 | 25.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 8.33% |
| Q3 2017 | -700.00% |
| Q2 2017 | 111.11% |
| Q1 2017 | -63.64% |
| Q4 2016 | 15.38% |
| Q3 2016 | 13.33% |
| Q2 2016 | 11.76% |